Novartis now sees net sales to grow high-single to low double-digit in FY24 and core operating income to grow low double-digit to mid-teens.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- NVS Earnings: Novartis Beats Q1 Estimates, Raises Outlook
- VGK vs. EZU: Which Is the Better European Stock ETF?
- Novartis announces data from the ALITHIOS study of Kesimpta
- Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
- MorphoSys board recommends shareholders accept Novartis offer